XF-73

XF-73 is an experimental antibiotic currently under development by Destiny Pharma. It is a member of the dicationic porphyrin family and is being developed for the prevention of post-surgical Staphylococcus aureus infections, including both methicillin-resistant (MRSA) and methicillin-sensitive (MSSA) strains.

Mechanism of Action[edit | edit source]

XF-73 functions by disrupting the bacterial membrane, leading to rapid bacterial death. Unlike many other antibiotics, XF-73 does not interfere with bacterial metabolic processes, which reduces the potential for the development of antibiotic resistance.

Clinical Trials[edit | edit source]

As of 2021, XF-73 has completed a Phase 2b clinical trial for the prevention of post-surgical Staphylococcus aureus infections. The trial demonstrated a significant reduction in the number of patients who developed a Staphylococcus aureus infection after surgery when treated with XF-73.

Potential Applications[edit | edit source]

In addition to its potential use in preventing post-surgical infections, XF-73 may also have applications in the treatment of other types of bacterial infections. Its broad-spectrum activity against both Gram-positive and Gram-negative bacteria suggests it could be used to treat a wide range of infections.